Immunotherapy combo aims to wipe out rectal cancer after radiation

NCT ID NCT05009069

First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 30 times

Summary

This study tests whether adding two immunotherapy drugs (atezolizumab and tiragolumab) after standard chemoradiation can help eliminate rectal cancer in people with locally advanced disease. About 58 adults with resectable rectal cancer will receive either the drug combination or atezolizumab alone before surgery. The main goal is to see if the cancer completely disappears in the removed tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Cancer Hospital

    Beijing, 100142, China

  • First Hospital of China Medical University

    Shenyang, 110001, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, 310009, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    Guangzhou, 510655, China

  • Zhongshan Hospital Fudan University

    Shanghai, 200032, China

Conditions

Explore the condition pages connected to this study.